

Meeting Format: Virtual Meeting.
Contact Person: M. Lourdes Ponce, Ph.D., Scientific Review Officer, Office of Scientific Review, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, 6701 Democracy Blvd., Democracy 1, Room 1073, Bethesda, MD 20892, 301-435-0810, lourdes.ponce@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Maximizing Investigators' Research Award.
Date: July 15–16, 2025.

Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.
Contact Person: Lauren Elizabeth Connell, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Dr., Room 710K, Bethesda, MD 20892, (301) 480-3629, connelle@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Cardiovascular Sciences.

Date: July 15, 2025.
Time: 9:30 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.
Contact Person: Sara Ahlgren, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Rm. 4136, Bethesda, MD 20892, 301-435-0904, sara.ahlgren@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Cellular Signaling and Biology of Aging.

Date: July 15, 2025.
Time: 9:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.
Contact Person: Birgit Neuhauser, Ph.D., Scientific Review Officer, srb Scientific Review Branch, National Institute on Aging, Gateway Building, Suite 2W-200, 7201 Wisconsin Avenue, Bethesda, MD 20892, 301-827-6548, birgit.neuhauser@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Molecular and Cellular Underpinnings and Integrative Neuropathophysiology of Alzheimer's Disease and Related Dementias (ADRD).

Date: July 15–16, 2025.
Time: 9:30 a.m. to 9:00 p.m.
Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.
Contact Person: Ashley Marie Kopec, Ph.D., Scientific Review Officer, Center for

Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 496-9293, kopecam@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships and Mentored Training: Hepatology, Toxicology, and Xenobiotic Metabolism and Disposition.

Date: July 15–16, 2025.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.
Contact Person: Charlene J. Repique, MS, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, 6707 Democracy Boulevard, Room 7347, Bethesda, MD 20892, (301) 451-3638, charlene.repique@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: June 10, 2025.

Sterlyn H. Gibson,
Program Specialist, Office of Federal Advisory Committee Policy.

[FR Doc. 2025-10892 Filed 6-13-25; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT: Brian Bailey at 240-669-5128, or brian.bailey@nih.gov. Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.

SUPPLEMENTARY INFORMATION:
 Technology description follows:

Pan-GI Norovirus Monoclonal Antibody and Its Use

Description of Technology

Norovirus is a leading cause of vomiting, diarrhea, and foodborne illness worldwide, with 700 million cases and 200,000 deaths occurring each year. Despite decades of work in the field, there are no preventive or therapeutic strategies specifically approved for even the most prevalent forms of human norovirus (*i.e.*, GI, GII genogroups), which are highly contagious and carry an increased risk of severe complications in children, older adults, and those with immunocompromising conditions.

Researchers at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID) have isolated the first broadly reactive monoclonal antibody against GI genogroup noroviruses (mAbs16E10) using samples from a human blood donor. Results of *in vitro* and *in vivo* analyses further supported the antibody's broad binding and blocking specificity to the entire GI norovirus genogroup, neutralization of the GI.1 type, and abrogation of infection in a non-human primate challenge. These complementary findings highlight the technology as a promising candidate for clinical applications, including prophylaxis for at-risk populations, diagnostics, and the development of candidate vaccines based on the newly discovered epitope.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404.

Potential Commercial Applications:

- Immunotherapy for immunocompromised populations
- Prophylactic treatment for at-risk populations
- Development of novel diagnostic, detection, and isolation methods
- Development of vaccine candidates that effectively induce broadly neutralizing antibodies with the potential to intervene against multiple noroviruses within the GI genogroup

Competitive Advantages:

- First broadly reactive monoclonal antibody against GI genogroup
- Exceptionally large binding epitope with high binding affinity
- Promising preliminary results in non-human primates

Development Stage: Preclinical.

Relevant Publications: Rimkute I, et al. A broadly protective human antibody

for GI genogroup noroviruses. *Nat Microbiol.* 2025. <https://doi.org/10.1038/s41564-025-01952-6>.

Inventors: Mario Roederer, Inga Rimkute, Peter Kwong, Adam Olia, Raffaello Verardi (all of NIAID VRC).

Intellectual Property: HHS Reference No. E-025-2024; Provisional Patent Application 63/653,691, filed on May 30, 2024.

Licensing Contact: To license this technology, please contact Brian Bailey at 240-669-5128 or brian.bailey@nih.gov at brian.bailey@nih.gov, and reference E-025-2024.

Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Brian Bailey at 240-669-5128 or brian.bailey@nih.gov, and reference E-025-2024.

Dated: June 9, 2025.

Surekha Vathyam,

Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.

[FR Doc. 2025-10921 Filed 6-13-25; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT: Terrence Joyce at 240-987-2347, or terrence.joyce@nih.gov. Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.

SUPPLEMENTARY INFORMATION: Technology description follows:

Francisella Lipids as Broad Anti-Inflammatory Therapeutics

Description of Technology

Anti-inflammatory treatments, particularly those used in the context of viral infection, have been shown to greatly inhibit the overall immune response, which can result in poor immunity and failure to control or clear the infection. Novel alternatives that can effectively attenuate inflammation without the more serious side effects of steroid medications (*e.g.*, global immune suppression, muscle weakness, etc.) may have substantial use across a wide range of disease areas.

Francisella tularensis (FT), the causative agent of tularemia, exhibits a potent ability to induce rapid suppression of inflammatory responses in host cells. Building on prior work that demonstrated the ability of crude and enriched lipids from virulent FT strains to dampen inflammation triggered by a variety of sources, researchers at the National Institute of Allergy and Infectious Disease (NIAID) have developed FT lipid preparations with strong potential for the prophylactic/therapeutic treatment of viral-mediated inflammation—without deleterious effects on the development of anti-viral immunity.

The NIAID data further show that these FT lipid preparations are relatively non-toxic to cells, do not adversely affect the functioning of T cells, and act in part by inhibiting production of inflammatory mediators, highlighting other potential therapeutic targets such as allergic and autoimmune-associated inflammation.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404.

Potential Commercial Applications:

- Well-tolerated, short-term prophylactic or therapeutic treatment of inflammation across multiple disease areas (viral infection, autoimmunity, etc.)

Competitive Advantages:

- Potential alternative that can overcome compromises to immunity and other side effects associated with traditional anti-inflammatory treatment

Development Stage: Preclinical.

Relevant Publications:

- Crane DD, et al. Lipids derived from virulent *Francisella tularensis* broadly inhibit pulmonary inflammation via toll-like receptor 2

and peroxisome proliferator-activated receptor α . *Clin Vaccine Immunol.* 2013;20(10):1531-1540.

- Ireland R, et al. *Francisella tularensis* SchuS4 and SchuS4 lipids inhibit IL-12p40 in primary human dendritic cells by inhibition of IRF1 and IRF8. *J Immunol.* 2013;191(3):1276-1286.

Inventors: Catherine Bosio, Glenn Nardone, Robin Ireland (all of NIAID)

Intellectual Property: HHS Reference No. E-142-2016; Provisional Patent Application 62/319,692, filed on April 7, 2016; 16,091,768, filed on October 5, 2018, issued December 20, 2022; PCT Application No. PCT/US2017/026467, filed on April 6, 2017; European Patent App. No 17721893.0, filed on April 6, 2017.

Licensing Contact: To license this technology, please contact Terrence Joyce at 240-987-2347 or terrence.joyce@nih.gov, and reference E-142-2016.

Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Terrence Joyce at 240-987-2347 or terrence.joyce@nih.gov, and reference E-142-2016.

Dated: June 9, 2025.

Surekha Vathyam,

Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.

[FR Doc. 2025-10919 Filed 6-13-25; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT: Wade Green at 301-761-7505, or